Total Cancer Care and ORIEN

The Total Cancer Care® protocol is used by all institutions within the Oncology Research Information Exchange Network (ORIEN), a collaboration among several of the leading cancer centers nationwide that was originally founded by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center.  

TCC and ORIEN objectives:

• Provide a standard system for studying large numbers of patients and their tissue samples for future research through a large tissue and data repository.
• Perform research grade whole exome sequencing and RNA sequencing for a subset of eligible patients
• Create collaborations for clinical trials amongst the ORIEN members to develop better therapeutic options for patients.

To have your patients enrolled in TCC, please email a list of your patients to MCCORIEN@uky.edu.

As part of the Total Cancer Care study, the project allows for sharing of specimen as well as clinical and genomic data, including whole exome and RNASeq data, to be used for future research studies. Researchers who are interested in using the data or specimen collected under this protocol must complete the data request form and complete a project proposal using this template.

Markey-led ORIEN Projects

• Assessing the Genomic Profile in Appalachian and non-Appalachian Patients with Colon Cancer.
  Theresa Bocklage, MD, and Zeta Chow, MD, University of Kentucky
• Assessment of Clinical, Genomic, Social and Structural Determinants of Health on Cancer Outcomes. 
  Jill Kolesar, PharmD, University of Kentucky; B. Lee Green, PhD, and Erin Siegel, PhD, MPH, Moffitt Cancer Center
• Causes of Cancer Disparities in Appalachia. 
  Jill Kolesar, PharmD, University of Kentucky
• Clinical and genomic profile of endometrial cancers including subgroup analysis of rare histologies. 
  Taylor Rives, MD, and Jill Kolesar, PharmD, University of Kentucky
• Comparison of clinical and genomic profile of breast cancers into subgroup analysis of rare histologies in Appalachian and non-Appalachian patients. 
  Rina Yadav, MD, Jill Kolesar, PharmD, and Jessica Moss, MD, University of Kentucky
• Comparison of the Oral and Tumor Microbiomes Between Appalachian and non-Appalachian patients. 
  Jill Kolesar, PharmD and Chi Wang, PhD, University of Kentucky; Daniel Spakowicz, PhD, The Ohio State University
• DACH1 Mutation Frequency in Endometrial Cancer. 
  Jill Kolesar, PharmD, University of Kentucky
• Defining tumor heterogeneity that predict therapeutic responses in lung cancer. 
  Christine Brainson, PhD, and Jinpeng Liu, PhD, University of Kentucky
• Determinants of Platinum Resistance in Ovarian Cancer. 
  Jill Kolesar, PharmD, University of Kentucky
• Molecular Landscape of Early Onset Oral Tongue Cancer. 
  Krystle Kuhs, PhD, MPH, and Jill Kolesar, PharmD, University of Kentucky
• Polo-like kinase expression analysis to predict treatment response in prostate cancer. 
  Snigdha Nutalapati, MD, and Zin Myint, MD, University of Kentucky
• Radiogenomic prognostic biomarker development for non-small cell lung cancer patients.
  Chi Wang, PhD, University of Kentucky

• Jill Kolesar, PharmD, MS, ORIEN Site Principal Investigator
• Rachel Miller, MD, Co-Investigator
• Susanne Arnold, MD, Co-Investigator
• Eric Durbin, DrPH, MS, Co-Investigator
• Therese Bocklage, MD, Co-Investigator

• Abby Anderson, Program Manager
• Elizabeth Belcher, MS, Program Coordinator
• Josiane Kai, Clinical Research Associate
• Lydia Williams, Clinical Research Associate 
• Darcy Adreon, Clinical Research Associate

For more information, visit the ORIEN homepage or email directly at mccorien@uky.edu.